These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 37436157)

  • 1. Microbiome Engineering Using Probiotic Yeast:
    Kim J; Atkinson C; Miller MJ; Kim KH; Jin YS
    Microbiol Spectr; 2023 Aug; 11(4):e0078023. PubMed ID: 37436157
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Durmusoglu D; Al'Abri IS; Collins SP; Cheng J; Eroglu A; Beisel CL; Crook N
    ACS Synth Biol; 2021 May; 10(5):1039-1052. PubMed ID: 33843197
    [No Abstract]   [Full Text] [Related]  

  • 3. Yeasts as probiotics: Mechanisms, outcomes, and future potential.
    Sen S; Mansell TJ
    Fungal Genet Biol; 2020 Apr; 137():103333. PubMed ID: 31923554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production of neoagarooligosaccharides by probiotic yeast Saccharomyces cerevisiae var. boulardii engineered as a microbial cell factory.
    Jin Y; Yu S; Liu JJ; Yun EJ; Lee JW; Jin YS; Kim KH
    Microb Cell Fact; 2021 Aug; 20(1):160. PubMed ID: 34407819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice.
    Everard A; Matamoros S; Geurts L; Delzenne NM; Cani PD
    mBio; 2014 Jun; 5(3):e01011-14. PubMed ID: 24917595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New biomarkers underlying acetic acid tolerance in the probiotic yeast Saccharomyces cerevisiae var. boulardii.
    Samakkarn W; Vandecruys P; Moreno MRF; Thevelein J; Ratanakhanokchai K; Soontorngun N
    Appl Microbiol Biotechnol; 2024 Jan; 108(1):153. PubMed ID: 38240846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saccharomyces boulardii alleviates allergic asthma by restoring gut microbiota and metabolic homeostasis via up-regulation of METTL3 in an m6A-dependent manner.
    Liu D; Hu L; Yang Y; Wang Y; Li Y; Su J; Wang G; Gong S
    Immunol Lett; 2024 Jun; 267():106853. PubMed ID: 38513836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing probiotic impact: engineering
    de Carvalho BT; Subotić A; Vandecruys P; Deleu S; Vermeire S; Thevelein JM
    Appl Environ Microbiol; 2024 Jun; 90(6):e0032524. PubMed ID: 38752748
    [No Abstract]   [Full Text] [Related]  

  • 9. A Mutation in
    Liu JJ; Zhang GC; Kong II; Yun EJ; Zheng JQ; Kweon DH; Jin YS
    Appl Environ Microbiol; 2018 May; 84(10):. PubMed ID: 29523547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strain engineering and metabolic flux analysis of a probiotic yeast Saccharomyces boulardii for metabolizing L-fucose, a mammalian mucin component.
    Kim J; Cheong YE; Yu S; Jin YS; Kim KH
    Microb Cell Fact; 2022 Oct; 21(1):204. PubMed ID: 36207743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programming Probiotics: Diet-Responsive Gene Expression and Colonization Control in Engineered
    Durmusoglu D; Haller DJ; Al'Abri IS; Day K; Sands C; Clark A; San-Miguel A; Vazquez-Uribe R; Sommer MOA; Crook NC
    ACS Synth Biol; 2024 Jun; 13(6):1851-1865. PubMed ID: 38787439
    [No Abstract]   [Full Text] [Related]  

  • 12.
    Yang Z; Wu Y; Liu X; Zhang M; Peng J; Wei H
    Nutrients; 2022 Aug; 14(17):. PubMed ID: 36079743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique genetic basis of the distinct antibiotic potency of high acetic acid production in the probiotic yeast
    Offei B; Vandecruys P; De Graeve S; Foulquié-Moreno MR; Thevelein JM
    Genome Res; 2019 Sep; 29(9):1478-1494. PubMed ID: 31467028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saccharomyces boulardii Administration Changes Gut Microbiota and Attenuates D-Galactosamine-Induced Liver Injury.
    Yu L; Zhao XK; Cheng ML; Yang GZ; Wang B; Liu HJ; Hu YX; Zhu LL; Zhang S; Xiao ZW; Liu YM; Zhang BF; Mu M
    Sci Rep; 2017 May; 7(1):1359. PubMed ID: 28465509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique Probiotic Properties and Bioactive Metabolites of Saccharomyces boulardii.
    Fu J; Liu J; Wen X; Zhang G; Cai J; Qiao Z; An Z; Zheng J; Li L
    Probiotics Antimicrob Proteins; 2023 Aug; 15(4):967-982. PubMed ID: 35608794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saccharomyces boulardii, a yeast probiotic, inhibits gut motility through upregulating intestinal serotonin transporter and modulating gut microbiota.
    Gu Y; Wang C; Qin X; Zhou B; Liu X; Liu T; Xie R; Liu J; Wang B; Cao H
    Pharmacol Res; 2022 Jul; 181():106291. PubMed ID: 35690329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial.
    Villar-García J; Güerri-Fernández R; Moya A; González A; Hernández JJ; Lerma E; Guelar A; Sorli L; Horcajada JP; Artacho A; D Auria G; Knobel H
    PLoS One; 2017; 12(4):e0173802. PubMed ID: 28388647
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Duysburgh C; Van den Abbeele P; Morera M; Marzorati M
    Benef Microbes; 2021 Aug; 12(4):59-73. PubMed ID: 34190033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic Engineering of Probiotic Saccharomyces boulardii.
    Liu JJ; Kong II; Zhang GC; Jayakody LN; Kim H; Xia PF; Kwak S; Sung BH; Sohn JH; Walukiewicz HE; Rao CV; Jin YS
    Appl Environ Microbiol; 2016 Apr; 82(8):2280-2287. PubMed ID: 26850302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving therapeutic protein secretion in the probiotic yeast Saccharomyces boulardii using a multifactorial engineering approach.
    Durmusoglu D; Al'Abri I; Li Z; Islam Williams T; Collins LB; Martínez JL; Crook N
    Microb Cell Fact; 2023 Jun; 22(1):109. PubMed ID: 37287064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.